http://hl7.org/fhir/uv/ebm/Citation/264329
type: Citation
node role: treeRoot
id:
  v: 264329
meta:
  version id:
    v: 15
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Citation 264329 version: 15; Last updated: 2025-10-13 12:34:35+0000; Language: en Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/Citation/264329 identifier: FEvIR Object Identifier/264329, https://pubmed.ncbi.nlm.nih.gov/37024129 title: 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2023-04-10 lastReviewDate: 2025-03-14 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of epublish statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2023-04-10 06:42:00+0000 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2023-04-06 20:43:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2023-04-07 06:00:00+0000 statusDate activity: PubMed Pubstatus of PMC release period: ?? --> 2023-04-06 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/37024129, https://www.ncbi.nlm.nih.gov/pmc//PMC10077111, https://doi.org/10.1136/bmj-2022-074068 Titles - Type Text * Primary title Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Abstracts - Type Text Copyright * Primary human use OBJECTIVE: To compare the benefits and harms of drug treatments for adults with type 2 diabetes,…
contained: Practitioner
  id:
    v: contributor0
  identifier:
    type:
      text:
        v: ORCID
    system:
      v: https://orcid.org/
      l: orcid.org
    value:
      v: 0000-0003-4299-5889
  name:
    family:
      v: Shi
    given:
      v: Qingyang
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Nong
    given:
      v: Kailei
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Vandvik
    given:
      v: Per Olav
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Guyatt
    given:
      v: Gordon H
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Schnell
    given:
      v: Oliver
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Rydén
    given:
      v: Lars
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Marx
    given:
      v: Nikolaus
contained: Practitioner
  id:
    v: contributor7
  name:
    family:
      v: Brosius
    given:
      v: Frank C
contained: Practitioner
  id:
    v: contributor8
  name:
    family:
      v: Mustafa
    given:
      v: Reem A
contained: Practitioner
  id:
    v: contributor9
  name:
    family:
      v: Agarwal
    given:
      v: Arnav
contained: Practitioner
  id:
    v: contributor10
  name:
    family:
      v: Zou
    given:
      v: Xinyu
contained: Practitioner
  id:
    v: contributor11
  name:
    family:
      v: Mao
    given:
      v: Yunhe
contained: Practitioner
  id:
    v: contributor12
  name:
    family:
      v: Asadollahifar
    given:
      v: Aminreza
contained: Practitioner
  id:
    v: contributor13
  name:
    family:
      v: Chowdhury
    given:
      v: Saifur Rahman
contained: Practitioner
  id:
    v: contributor14
  name:
    family:
      v: Zhai
    given:
      v: Chunjuan
contained: Practitioner
  id:
    v: contributor15
  name:
    family:
      v: Gupta
    given:
      v: Sana
contained: Practitioner
  id:
    v: contributor16
  name:
    family:
      v: Gao
    given:
      v: Ya
contained: Practitioner
  id:
    v: contributor17
  name:
    family:
      v: Lima
    given:
      v: João Pedro
contained: Practitioner
  id:
    v: contributor18
  name:
    family:
      v: Numata
    given:
      v: Kenji
contained: Practitioner
  id:
    v: contributor19
  name:
    family:
      v: Qiao
    given:
      v: Zhi
contained: Practitioner
  id:
    v: contributor20
  name:
    family:
      v: Fan
    given:
      v: Qinlin
contained: Practitioner
  id:
    v: contributor21
  name:
    family:
      v: Yang
contained: ArtifactAssessment

v: PRN

v: Provider number

v: Qinbo

Practitioner
id:
  v: contributor22
name:
  family:
    v: Jin
  given:
    v: Yinghui

Practitioner
id:
  v: contributor23
name:
  family:
    v: Ge
  given:
    v: Long

Practitioner
id:
  v: contributor24
name:
  family:
    v: Yang
  given:
    v: Qiuyu

Practitioner
id:
  v: contributor25
name:
  family:
    v: Zhu
  given:
    v: Hongfei

Practitioner
id:
  v: contributor26
name:
  family:
    v: Yang
  given:
    v: Fan

Practitioner
id:
  v: contributor27
name:
  family:
    v: Chen
  given:
    v: Zhe

Practitioner
id:
  v: contributor28
name:
  family:
    v: Lu
  given:
    v: Xi

Practitioner
id:
  v: contributor29
name:
  family:
    v: He
  given:
    v: Siyu

Practitioner
id:
  v: contributor30
name:
  family:
    v: Chen
  given:
    v: Xiangyang

Practitioner
id:
  v: contributor31
name:
  family:
    v: Lyu
  given:
    v: Xiafei

Practitioner
id:
  v: contributor32
name:
  family:
    v: An
  given:
    v: Xingxing

Practitioner
id:
  v: contributor33
name:
  family:
    v: Chen
  given:
    v: Yaolong

Practitioner
id:
  v: contributor34
name:
  family:
    v: Hao
  given:
    v: Qiukui

Practitioner
id:
  v: contributor35
name:
  family:
    v: Standl
  given:
    v: Eberhard

Practitioner
id:
  v: contributor36
name:
  family:
    v: Siemieniuk
  given:
    v: Reed

Practitioner
id:
  v: contributor37
name:
  family:
    v: Agoritsas
  given:
    v: Thomas

Practitioner
id:
  v: contributor38
name:
  family:
    v: Tian
  given:
    v: Haoming

Practitioner
id:
  v: contributor39
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: PRN
      display:
        v: Provider number
    text:
      v: ORCID
  system:
    v: https://orcid.org/
    l: orcid.org
  value:
    v: 0000-0003-0060-0287
name:
  family:
    v: Li
  given:
    v: Sheyu

ArtifactAssessment
id:
  v: meshHeading0
artifact: Reference
  l: #
  reference:
    v: #
  type:
    v: Citation
    l: Citation
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D000328
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000328
      display:
        v: Adult
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is not a major topic
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D006801
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D006801
      display:
        v: Humans
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is not a major topic
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D003924
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D003924
      display:
        v: Diabetes Mellitus, Type 2
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is Major topic
  component:
    type:
      text:
        v: qualifier
    classifier:
      coding: Q000188
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: http://id.nlm.nih.gov/mesh/D000077203
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000077203
      display:
        v: Sodium-Glucose Transporter 2 Inhibitors
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is Major topic
  component:
    type:
      text:
        v: qualifier
    classifier:
      coding: Q000009
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D000451
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000451
      display:
        v: Mineralocorticoid Receptor Antagonists
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is not a major topic
  component:
    type:
      text:
        v: qualifier
    classifier:
      coding: Q000009
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: http://id.nlm.nih.gov/mesh/D000071076
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh

v: Q000188

v: drug therapy

v: is Major topic

system:
  v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
  l: Thesaurus.owl
code:
  v: C49487
display:
  v: No

v: Q000009

v: adverse effects

v: is Major topic

system:
  v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
  l: Thesaurus.owl
code:
  v: C49487
display:
  v: No

v: Q000009

v: adverse effects

v: is Major topic

system:
  v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
  l: Thesaurus.owl
code:
  v: C49487
display:
  v: No

v: D000071076

v: Network Meta-Analysis

v: false

v: true

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000067757
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000067757
    display:
      v: Glucagon-Like Peptide-1 Receptor
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000627
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D011788
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D011788
    display:
      v: Quality of Life
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D007676
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D007676
    display:
      v: Kidney Failure, Chronic
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is Major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D006333
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D006333
    display:
      v: Heart Failure
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000188
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000188
      display:
        v: drug therapy
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D016032
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016032
    display:
      v: Randomized Controlled Trials as Topic
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 264329
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 37024129

v: 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

v: active

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: Computable Publishing LLC

telecom:
  system:
    v: email

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

v: 2023-04-10

v: 2025-03-14

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: pubmed-publication-status-epublish
  display:
    v: PubMed PublicationStatus of epublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2023-04-10T06:42:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2023-04-06T20:43:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2023-04-07T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pmc-release
    display:
      v: PubMed Pubstatus of PMC release
period:
  end:
    v: 2023-04-06

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 37024129
identifier:
  system:
    v: https://www.ncbi.nlm.nih.gov/pmc/
    l: pmc
  value:
    v: PMC10077111
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1136/bmj-2022-074068
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  text:
    v: Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **OBJECTIVE:** To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options. <AbstractText Label="DESIGN">Systematic review and network meta-analysis. <AbstractText Label="DATA SOURCES">Ovid Medline, Embase, and Cochrane Central up to 14 October 2022. <AbstractText Label="ELIGIBILITY CRITERIA FOR SELECTING STUDIES">Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach. **RESULTS:** The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and e…
  copyright:
    v: © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Gregg EW, Jakicic JM, Blackburn G, et al. Look AHEAD Research Group . Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-21. 10.1016/S2213-8587(16)30162-0.
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/27595918/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/27595918/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 27595918
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Palmer SC, Tendal B, Mustafa RA, et al. . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 10.1136/bmj.m4573.
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/33441402/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/33441402/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 33441402
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Li S, Vandvik PO, Lytvyn L, et al. . SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 2021;373:n1091. 10.1136/bmj.n1091.
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/33975892/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/33975892/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 33975892
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD Investigators . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29. 10.1056/NEJMoa2025845.
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/33264825/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/33264825/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 33264825
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63. 10.1056/NEJMoa2110956.
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/34449181/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/34449181/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov
      value:
        v: 34449181
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Rosenstock J, Wysham C, Frías JP, et al. . Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55. 10.1016/S0140-6736(21)01324-6.
  target: Reference
    l: https://pubmed.ncbi.nlm.nih.gov/34186022/
    reference:
      v: https://pubmed.ncbi.nlm.nih.gov/34186022/
    type:
      v: Citation
      l: Citation
    identifier:
      system:
        v: https://pubmed.ncbi.nlm.nih.gov
        l: pubmed.ncbi.nlm.nih.gov

v: NLM

v: NLM

v: NLM

v: NLM

v: NLM

v: 34186022

display:
  v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Frías JP, Davies MJ, Rosenstock J, et al. SURPASS-2 Investigators . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-15. 10.1056/NEJMoa2107519.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/34170647/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/34170647/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 34170647
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Ludvik B, Giorgino F, Jódar E, et al. . Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:583-98. 10.1016/S0140-6736(21)01443-4.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/34370970/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/34370970/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 34370970
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24. 10.1016/S0140-6736(21)02188-7.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/34672967/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/34672967/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 34672967
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Dahl D, Onishi Y, Norwood P, et al. . Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA 2022;327:534-45. 10.1001/jama.2022.0078.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/35133415/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/35133415/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 35133415
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Rydén L, Standl E. After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk. N Engl J Med 2022;387:1136-8. 10.1056/NEJMe2210531.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/36130002/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/36130002/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 36130002
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Nathan DM, Lachin JM, Balasubramanyam A, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022;387:1063-74. 10.1056/NEJMoa2200433.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/36129996/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/36129996/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 36129996
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Nathan DM, Lachin JM, Bebu I, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075-88. 10.1056/NEJMoa2200436.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/36129997/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/36129997/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 36129997
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Marx N, Ryden L, Brosius F, et al. . Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Res Clin Pract 2021;177:108870. 10.1016/j.diabres.2021.108870.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/34044026/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/34044026/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 34044026
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 10.1136/bmj.n71.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/33782057/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/33782057/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 33782057
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Hutton B, Salanti G, Caldwell DM, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. 10.7326/M14-2385.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/26030634/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/26030634/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 26030634
    assigner:
      display:
        v: NLM

type:
  v: cites
citation:
  v: Guyatt G, Busse J. Methods Commentary: Risk of Bias in Randomized Trials 1. DistillerSR. 2011. https://www.distillersr.com/resources/methodological-resources/risk-of-bias-commentary.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Levin A, Agarwal R, Herrington WG, et al. participant authors of the International Society of Nephrology’s 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials . International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020;98:849-59. 10.1016/j.kint.2020.07.013.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/32998816/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/32998816/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 32998816
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24. 10.1002/jrsm.1058.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/26053424/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/26053424/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 26053424
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Shi Q, Wang Y, Hao Q, et al. . Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022;399:259-69. 10.1016/S0140-6736(21)01640-8.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/34895470/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/34895470/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 34895470
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Bhaumik DK, Amatya A, Normand S-L, et al. . Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67. 10.1080/01621459.2012.664484.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/23734068/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/23734068/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 23734068
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110. 10.1002/jrsm.1044.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/26062084/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/26062084/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 26062084
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med 2013;32:5414-29. 10.1002/sim.6001.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/24123165/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/24123165/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 24123165
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Wiksten A, Hawkins N, Piepho H-P, Gsteiger S. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. Value Health 2020;23:918-27. 10.1016/j.jval.2020.03.010.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/32762994/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/32762994/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 32762994
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Efthimiou O, Rücker G, Schwarzer G, Higgins JPT, Egger M, Salanti G. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019;38:2992-3012. 10.1002/sim.8158.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/30997687/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/30997687/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 30997687
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Schandelmaier S, Briel M, Varadhan R, et al. . Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901-6. 10.1503/cmaj.200077.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/32778601/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/32778601/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 32778601
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Balshem H, Helfand M, Schünemann HJ, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. 10.1016/j.jclinepi.2010.07.015.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/21208779/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/21208779/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 21208779
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Davies AL, Papakonstantinou T, Nikolakopoulou A, Rücker G, Galla T. Network meta-analysis and random walks. Stat Med 2022;41:2091-114. 10.1002/sim.9346.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/35293631/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/35293631/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 35293631
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/25252733/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/25252733/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 25252733
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 2021;137:163-75. 10.1016/j.jclinepi.2021.03.026.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/33857619/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/33857619/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 33857619
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 2022;150:216-24. 10.1016/j.jclinepi.2022.07.014
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/35934265/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/35934265/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 35934265
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE working group . GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. 10.1136/bmj.m3900.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/33177059/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/33177059/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 33177059
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Phillips MR, Sadeghirad B, Busse JW, et al. . Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open 2022;12:e056400. 10.1136/bmjopen-2021-056400.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/35688599/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/35688599/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 35688599
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Buchan TA, Malik A, Chan C, et al. . Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Heart 2021;107:1962-73. 10.1136/heartjnl-2021-319243.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/33833070/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/33833070/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 33833070
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Wright AK, Carr MJ, Kontopantelis E, et al. . Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care 2022;45:909-18. 10.2337/dc21-1113.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/35100355/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/35100355/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 35100355
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Rossing P, Anker SD, Filippatos G, et al. FIDELIO-DKD and FIGARO-DKD Investigators . Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 2022;45:2991-8. 10.2337/dc22-0294.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/35972218/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/35972218/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 35972218
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Sato N, Ajioka M, Yamada T, et al. ARTS-HF Japan study group . A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J 2016;80:1113-22. 10.1253/circj.CJ-16-0122.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/27074824/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/27074824/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 27074824
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Ruilope LM, Pitt B, Anker SD, et al. . Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant 2023;38:372-83.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/35451488/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/35451488/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 35451488
    assigner:
      display:
        v: NLM

type:
  v: cites
citation:
  v: Bayer. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%). Clinicaltrials.gov. 2022. https://clinicaltrials.gov/ct2/show/NCT04435626.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol Res 2021;172:105835. 10.1016/j.phrs.2021.105835.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/34438065/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/34438065/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 34438065
    assigner:
      display:
        v: NLM

type:
  v: cites
citation:
  v: Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov 2022. https://clinicaltrials.gov/ct2/show/NCT04255433.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:642-53. 10.1038/s41574-020-0399-8.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/32929230/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/32929230/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 32929230
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Liu J, Li L, Li S, et al. . Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22:1619-27. 10.1111/dom.14075.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/32364674/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/32364674/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 32364674
    assigner:
      display:
        v: NLM

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Lin C, Zhu X, Cai X, et al. . SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol 2021;20:91. 10.1186/s12933-021-01276-9.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/33910574/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/33910574/
  type:
    v: Citation
    l: Citation
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 33910574
    assigner:
      display:
        v: NLM

type:
  v: comment-in
classifier:
  coding: D016420
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Acad Emerg Med. 2024 Aug;31(8):832-834. doi: 10.1111/acem.14922.
target: Reference
  l: https://pubmed.ncbi.nlm.nih.gov/38661224/
  reference:
    v: https://pubmed.ncbi.nlm.nih.gov/38661224/
  identifier:
    system:
      v: https://pubmed.ncbi.nlm.nih.gov
      l: pubmed.ncbi.nlm.nih.gov
    value:
      v: 38661224
    assigner:
      display:
        v: NLM

published in:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/published-in-type
        l: published-in-type
      code:
        v: D020492
      display:
        v: Periodical
  identifier:
    type:
      text:
        v: Electronic ISSN Type
    system:
      v: https://portal.issn.org
      l: portal.issn.org
    value:
      v: 1756-1833
  identifier:
    type:
      text:
        v: ISOAbbreviation
    system:
      v: https://www.issn.org/services/online-services/access-to-the-ltwa/
      l: access-to-the-ltwa
    value:
      v: BMJ
  identifier:
    type:
      text:
        v: ISSN Linking
    system:
      v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
      l: the-issn-l-for-publications-on-multiple-media
    value:
      v: 0959-8138
  identifier:
    type:
      text:
        v: Medline Title Abbreviation
    system:
      v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
      l: contructitleabbre.html
    value:
      v: BMJ
  identifier:
    type:
      text:
        v: NLM Unique ID
    system:
      v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
    value:
      v: 8900488
  title:
    v: BMJ (Clinical research ed.)
  publisher location:
    v: England
cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet
    display:
      v: Internet
volume:
  v: 381
article date:
  v: 2023-04-06
page string:
  v: e074068

v: Electronic

v: Electronic

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2023-04-06

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/37024129/
  l: https://pubmed.ncbi.nlm.nih.gov/37024129/

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1136/bmj-2022-074068
  l: bmj-2022-074068

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Electronic
    display:
      v: Electronic
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000077203
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000077203
    display:
      v: Sodium-Glucose Transporter 2 Inhibitors
    user selected:
      v: false
classifier:
  coding: D000451
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000451
    display:
      v: Mineralocorticoid Receptor Antagonists
    user selected:
      v: false
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000067757
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000067757
    display:
      v: Glucagon-Like Peptide-1 Receptor
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier:
  coding: D017418
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017418
    display:
      v: Meta-Analysis
    user selected:
      v: false
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000078182
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000078182
    display:
      v: Systematic Review
    user selected:
      v: false
classifier:
  coding: D016428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Shi Q
  forename initials:
    v: Q
  affiliation:
    display:
      v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Nong K
  forename initials:
    v: K
  affiliation:
    display:
      v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Vandvik PO
  forename initials:
    v: PO
  affiliation:
    display:
      v: Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Guyatt GH
  forename initials:
    v: GH
  affiliation:
    display:
      v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Schnell O
  forename initials:
    v: O
  affiliation:
    display:
      v: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Rydén L
  forename initials:
    v: L
  affiliation:
    display:
      v: Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Marx N
  forename initials:
    v: N
  affiliation:
    display:
      v: Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany.
entry:
  contributor:
    l: contributor7
    reference:
      v: #contributor7
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Brosius FC
  forename initials:
    v: FC
  affiliation:
    display:
      v: Division of Nephrology, University of Arizona College of Medicine Tucson, Tucson, AZ, USA.
entry:
  contributor:
    l: contributor8
    reference:
      v: #contributor8
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Mustafa RA
  forename initials:
    v: RA
  affiliation:
    display:
      v: Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, MI, USA.
entry:
  contributor:
    l: contributor9
    reference:
      v: #contributor9
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Agarwal A
  forename initials:
    v: A
  affiliation:
    display:
      v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
  affiliation:
    display:
      v: Department of Medicine, McMaster University, Hamilton, ON, Canada.
entry:
  contributor:
    l: contributor10
    reference:
      v: #contributor10
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Zou X
  forename initials:
    v: X
  affiliation:
    display:
      v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor11
    reference:
      v: #contributor11
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Mao Y
  forename initials:
    v: Y
  affiliation:
    display:
      v: Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor12
    reference:
      v: #contributor12
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Asadollahifar A
  forename initials:
    v: A
  affiliation:
    display:
      v: Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

contributor:
  l: contributor13
  reference:
    v: #contributor13
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chowdhury SR
forename initials:
  v: SR
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor14
  reference:
    v: #contributor14
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Zhai C
forename initials:
  v: C
affiliation:
  display:
    v: Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.

contributor:
  l: contributor15
  reference:
    v: #contributor15
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Gupta S
forename initials:
  v: S
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor16
  reference:
    v: #contributor16
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Gao Y
forename initials:
  v: Y
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
affiliation:
  display:
    v: Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor17
  reference:
    v: #contributor17
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Lima JP
forename initials:
  v: JP
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor18
  reference:
    v: #contributor18
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Numata K
forename initials:
  v: K
affiliation:
  display:
    v: Department of Emergency Medicine, St Marianna University School of Medicine, Kawasaki, Japan.

contributor:
  l: contributor19
  reference:
    v: #contributor19
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Qiao Z
forename initials:
  v: Z
affiliation:
  display:
    v: West China School of Medicine, Sichuan University, Chengdu, China.

contributor:
  l: contributor20
  reference:
    v: #contributor20
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Fan Q
forename initials:
  v: Q
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor21
  reference:
    v: #contributor21
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Yang Q
forename initials:
  v: Q
affiliation:
  display:
    v: Department of Nephrology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor22
  reference:
    v: #contributor22
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Jin Y
forename initials:
  v: Y
affiliation:
  display:
    v: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.

contributor:
  l: contributor23
  reference:
    v: #contributor23
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Ge L
forename initials:
  v: L
affiliation:
  display:
    v: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor24
  reference:
    v: #contributor24
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Yang Q
forename initials:
  v: Q
affiliation:
  display:
    v: Evidence-Based Nursing Centre, School of Nursing, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor25
  reference:
    v: #contributor25
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Zhu H
forename initials:
  v: H
affiliation:
  display:
    v: Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor26
  reference:
    v: #contributor26
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Yang F
forename initials:
  v: F
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Chengdu Fifth People's Hospital, Chengdu, China.

contributor:
  l: contributor27
  reference:
    v: #contributor27
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chen Z
forename initials:
  v: Z
affiliation:
  display:
    v: Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

contributor:
  l: contributor28
  reference:
    v: #contributor28
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Lu X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor29
  reference:
    v: #contributor29
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: He S
forename initials:
  v: S
affiliation:
  display:
    v: Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor30
  reference:
    v: #contributor30
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chen X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, First People's Hospital of Shuangliu District, Chengdu, China.

contributor:
  l: contributor31
  reference:
    v: #contributor31
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Lyu X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor32
  reference:
    v: #contributor32
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: An X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor33
  reference:
    v: #contributor33
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chen Y
forename initials:
  v: Y
affiliation:
  display:
    v: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor34
  reference:
    v: #contributor34
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Hao Q
forename initials:
  v: Q
affiliation:
  display:
    v: School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.

contributor:
  l: contributor35
  reference:
    v: #contributor35
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Standl E
forename initials:
  v: E
affiliation:
  display:
    v: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.

contributor:
  l: contributor36
  reference:
    v: #contributor36
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Siemieniuk R
forename initials:
  v: R
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor37
  reference:
    v: #contributor37
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Agoritsas T
forename initials:
  v: T
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
affiliation:
  display:
    v: Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.

contributor:
  l: contributor38
  reference:
    v: #contributor38
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Tian H
forename initials:
  v: H
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor39
  reference:
    v: #contributor39
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Li S
forename initials:
  v: S
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China lisheyu@gmail.com.